Clinical trial NCT06580444: Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Official title: Brexanolone to Target Concurrent Posttraumatic Stress Disorder (PTSD) and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Alcohol Use Disorder (AUD)
Post Traumatic Stress Disorder (PTSD)
Keywords: Alcohol Used Disorder (AUD)
Post Traumatic Stress Disorder (PTSD)
Alcohol Use
Heavy Drinkers
Brexanolone
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
name: Congressionally Directed Medical Research Programs
name: VA Connecticut Healthcare System
name: Sage Therapeutics
name: RTI International
name: Yale University
First posted: 2024-08-30
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: At baseline, participants who meet eligibility criteria are randomized to placebo or 90, 60, or 30 mcg/kg/h doses of BREX along with the order/sequence of their stress and neutral lab sessions in a double-mask fashion for the duration of the study. The treatment allocation will be equal in each arm. Additionally, the order/sequence of stress and neutral laboratory sessions will be randomized for laboratory sessions (e.g., if stress on session #1 then neutral on session #2) in a manner that assures treatment balance within laboratory session.

Each participant will be randomized to receive a target dose of either 90, 60, 30 and 0 mcg/kg/h, titrated over the 20 hours; both the 90 and 60 doses have shown efficacy to target postpartum depressive symptoms and the 30 mcg/kg/h will test the lower limits of efficacy.

The sample size will have 10 participants in each group for doses 0, 30, 60 and 90 to equal 40 participants.
Primary purpose: OTHER

Brief summary: The purpose of this research study is to find out how Zulresso®/brexanolone influences Posttraumatic Stress Disorder (PTSD) symptoms and alcohol use.

Detailed description: The overall objectives of this study are to establish the safety of administering 90, 60, and 30mcg/kg/h target doses of brexanolone (BREX; 20-hour infusion; versus placebo) and investigate efficacy of each dose to reduce PTSD symptoms, alcohol consumption, and stress reactivity via mood-induction paradigms in individuals with PTSD/AUD.

The primary aims of this study are to:

1. Evaluate the safety and tolerability of BREX 90, 60, and 30 mcg/kg/h among individuals with PTSD/AUD
2. Investigate the medication effect of the 90, 60, and 30 mcg/kg/h doses of BREX to reduce alcohol consumption and PTSD symptoms in men and women with PTSD/AUD.

The secondary aim of this study is to:

1. Investigate the medication effect of each of the 90, 60, 30 mcg/kg/h doses of BREX to reduce stress reactivity via mood-induction paradigm in men and women with PTSD/AUD.

The exploratory aim of this study is to:

1. Explore sex-specific responses to brexanolone's effect on PTSD and alcohol use among men and women with PTSD/AUD.

Eligibility criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form.
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Male or female, aged 21-70 years old, either active duty or with a history of US military service.
4. Current DSM-5 diagnostic criteria for AUD (mild, moderate, or severe) within 6 months at the time of the intake, as measured via Quick Structured Clinical Interview for DSM-5 (QuickSCID-5), as well as the following drinking criteria (measured by the Timeline Followback):

   1. Men: drink greater than 14 drinks per week and exceed five drinks per day at least once per week within the past 30 days at the time of intake.
   2. Women: drink greater than 7 drinks per week and exceed four drinks per day at least once per week within the past 30 days at the time of intake.
   3. Men and women will not endorse a desire to completely abstain from alcohol use at any point during the study. It will be necessary to confirm, via self-report (TLFB), consumption of alcohol within the week prior to the alcohol laboratory sessions. In the event the TLFB indicates recent abstinence, participants will be explicitly queried regarding desire to completely abstain from alcohol use moving forward, utilizing a one question item. If a patient completes the drug administration session, but then endorses desire to abstain completely he/she will be followed via observation and not participate in laboratory sessions, in which alcohol is self-administered.
5. Have a Clinician Administered PTSD Scale for DSM-5 (CAPS-5) total score ≥26 for the past month at intake, as well as a PTSD Checklist for DSM-5 (PCL-5) total score ≥31 for the past month at intake.
6. Not currently taking medications thought to influence alcohol consumption such as Acamprosate, formulations of naltrexone, topiramate, ondansetron, baclofen, disulfiram, or gabapentin within 30 days prior to enrollment.
7. Females of childbearing potential, who are not surgically sterilized (tubal ligation/hysterectomy) or not post-menopausal (no menstrual period for \> 6 months) must be willing to use a medically acceptable and effective birth control method for at least 1 month prior to screening, randomization and intake and while participating in the study. Medically acceptable methods of contraception that may be used by the participant include abstinence, birth control pills, patches, implants, injections, rings, diaphragm, intrauterine device (IUD), or condoms.

Exclusion Criteria:

1. Meets current DSM-5 diagnostic criteria for schizophrenia, bipolar disorder, and/or other severe mental illnesses, as defined by the QuickSCID-5 at intake. Please note that the QuickSCID-5 provides a Psychotic Symptom Screen. In the event, a patient screens positive for psychotic symptoms, the study team member will administer Modules B (Psychotic and Associated Symptoms) and C (Differential Diagnosis of Psychotic Disorders) from the Structured Clinician Interview for DSM-5 Clinician Version to determine a diagnosis of schizophrenia or another psychotic disorder.
2. Increased risk of suicide that necessitates inpatient treatment or warrants therapy excluded by the protocol, and/or a current suicidal plan, per investigator's clinical judgement during interview.
3. Treatment with trauma-focused therapy (e.g., Cognitive Processing Therapy, Prolonged Exposure Therapy, or Eye Movement Desensitization \& Reprocessing Therapy) for PTSD within two weeks of intake (if participant is receiving therapy, he/she must complete treatment prior to entering study). Note: Supportive psychotherapy in process at time of Screening may be continued.
4. Meets criteria for current diagnosis of moderate or severe non-alcohol substance use disorder (except for caffeine and nicotine), as measured via QuickSCID-5, during the preceding 1 month relative to intake, per PI discretion, based on participant's screening interview.
5. Tests positive for illicit substances during urine toxicology screens (except cannabis) at intake session. Patients who utilize cannabis but do not meet substance use disorder criteria are permitted.
6. Self-reported past 30-day use at intake of psychoactive drugs (except cannabis), including opioids, CNS depressants (such as benzodiazepines), use of psychotropic medications in the class of antipsychotics, mood stabilizers, or stimulants. Note: Participant use of stable doses (prescribed for \>2 months and the current dose has been stable or ≥3 weeks at intake) of antidepressants will be reviewed by Study MD.
7. Likely to exhibit clinically significant alcohol withdrawal during the study. Specifically, we will exclude subjects who a) have a history of perceptual distortions, seizures, delirium, or hallucinations upon withdrawal, assessed during physical examination as part of intake procedures or b) have a score of \> 8 on the Clinical Institute Withdrawal Assessment scale at intake appointment. Participants must have a CIWA-Ar score of \< 8 prior to randomization.
8. Any clinically significant, uncontrolled, or medical/surgical condition, that at the discretion of the investigator, would contraindicate use of brexanolone, or limit ability to complete study assessments, including end stage renal disease, significant arrhythmia or heart block, or heart failure, severe thrombocytopenia or hemophilia, severe hepatic failure, complete hearing loss, and/or need for surgery that might interfere with ability to participate. Such conditions will be assessed by the Study MD based upon physical examination (including review of medical history), as well as review of medical records, ECG and basic blood chemistries (i.e., CBC).
9. Females who are pregnant, nursing, planning to become pregnant or fail to use one of the following methods of birth control during study participation (unless she or her partner is surgically sterile, or she is postmenopausal). Birth control includes: hormonal contraceptives (oral, implant, injection, patch, or ring), contraceptive sponge, double barrier (diaphragm or condom plus spermicide) or IUD.
10. Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the study visit schedule or requirements.

Primary outcomes:
measure: Severity and numbers of treatment-emergent AEs
timeFrame: From onset of Brexanolone administration until 30-day follow up.
measure: Change in Heart Rate from onset of Brexanolone administration until discharge from the drug administration session.
timeFrame: An average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)
measure: Change in Blood Pressure from onset of Brexanolone administration until discharge from the drug administration session.
timeFrame: An average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)
measure: Change in Cortisol from onset of Brexanolone administration until discharge from the drug administration session.
timeFrame: FAn average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)
measure: Change in percentage of milliliters of alcohol consumed during the 2-hour ad-libitum drinking paradigm between laboratory sessions (stress vs. neutral).
timeFrame: During the 2-hour ad-libitum drinking paradigm between lab sessions (stress Vs Neutral)
measure: Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until 30-day follow-up
timeFrame: From intake, day 0 through day 37 (30-day follow-up).
measure: Change in Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until end of dosing.
timeFrame: An average of 22 hours (From intake, day 0 through end of infusion on Day 2)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assistant Professor Psychiatry
name: MacKenzie R. Peltier, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: